Toni K. Choueiri, MD is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. He is the Medical Director, International Strategic Initiatives at DFCI and past President of the Medical Staff at DFCI. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, KidneyCan Board as Chair (2023-), American Society of Clinical Oncology (ASCO) Board (2024-2028), the National Cancer Institute (NCI) GU Steering Committee, and is past Chairman (2015-2018) of the Medical and Scientific Steering Committee of the Kidney Cancer Association (KCA). Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI) and the Association of American Physicians (AAP). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania. He received the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI in 2013, the Eugene Schonfeld Award from the KCA in 2016, and was a Giants of Cancer Care inductee in 2021. He was awarded the King Hussein Cancer Research Lifetime Achievement Award in 2023 and the American Association for Cancer Research Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research in 2025. He received in 2024 and 2025 Honoris Causa Doctorates from the Lebanese University and Université Saint Joseph de Beyrouth, respectively.

Dr. Choueiri is interested in developing novel experimental therapies and biomarkers in GU malignancies, including renal cell carcinoma (RCC). In a series of landmark studies on which he was either first or senior author, Dr. Choueiri and colleagues have made seminal observations that have defined and evolved the treatment of metastatic RCC and led to the approval of several therapies such as Cabozantinib, Pazopanib, Avelumab+Axitinib, Cabozantinib+Nivolumab, Pembrolizumab+Lenvatinib, and Belzutifan, as well as adjuvant pembrolizumab for resected RCC at high risk of relapse. His research also focuses on the epidemiology, diagnosis, and treatment outcomes of GU cancers, especially through having co-established the International Metastatic RCC Database Consortium criteria for RCC risk stratification. His laboratory has contributed translational studies that have shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy, as well as pioneering personalized neoantigen vaccine strategies. Dr. Choueiri led work that contributed to our understanding of the underlying biology and rationale for therapies in rare histological kidney cancer subtypes including papillary, translocation, and sarcomatoid RCC. His work on liquid biopsy pioneered a first-in-class comprehensive epigenomic liquid biopsy platform of circulating chromatin.

Dr. Choueiri has received research funding from the NCI, the Department of Defense (DOD), and foundation and industry partners. His work has been published in journals such as the New England Journal of Medicine, JAMA, Nature, Nature Medicine, Science, The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He has an H-index of 160 (Google scholar, April 15, 2025). He lectures frequently around the world. He has over 900 PubMed-indexed publications and is the lead investigator of multiple national and international phase I-III clinical trials in GU cancers.